Remarkably, another goal of the study was to demonstrate that although the in vitro proliferation capacity of genetic engineered cells was not different from mock control cells, KM12C cells overexpressing SPRYD7 showed an increased tumor growth ability in vivo, equal to the growth capacity of KM12SM cells, which suggest that the overexpression of SPRYD7 induce changes in the tumoral microenvironment (TME), enhancing CRC development and progression. Here, SPRYD7 is linked to colorectal carcinoma.